Evidence map›Paper›PMID 29416653›Full record

ArticleOncotarget2018

Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum.

Arunangshu Ghoshal, Hans Garmo, Rhonda Arthur, Paul Carroll, Lars Holmberg, Niklas Hammar, Ingmar Jungner, Håkan Malmström, Mats Lambe, Göran Walldius and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Arunangshu GhoshalKing's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology Research, London, UK.
Hans GarmoKing's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology Research, London, UK.
Rhonda ArthurKing's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology Research, London, UK.
Paul CarrollEndocrinology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Lars HolmbergKing's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology Research, London, UK.
Niklas HammarUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Ingmar JungnerDepartment of Medicine, Clinical Epidemiological Unit, Karolinska Institutet and CALAB Research, Stockholm, Sweden.
Håkan MalmströmDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Mats LambeRegional Cancer Centre, Uppsala University, Uppsala, Sweden.
Göran WalldiusUnit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Mieke Van HemelrijckKing's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology Research, London, UK.
King's College London · GBKarolinska Institutet · SELondon Cancer · GBAstraZeneca (Sweden) · SEGuy's and St Thomas' NHS Foundation Trust · GBRegional Research Council in Uppsala-Örebro Region · SESwedish Orphan Biovitrum (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic inflammation is one of the underlying risks associated with thyroid cancer. We ascertained the association between commonly measured serum biomarkers of inflammation and the risk of thyroid cancer in Swedish Apolipoprotein-related MORtality RISk (AMORIS) study. 226,212 subjects had baseline measurements of C-reactive protein, albumin and haptoglobin. Leukocytes were measured in a subgroup of 63,845 subjects. Associations between quartiles and dichotomized values of inflammatory markers and risk of thyroid cancer were analysed using multivariate Cox proportional hazard models. 202 individuals were diagnosed with thyroid cancer during a mean follow-up of 19.6 years. There was a positive association between lower albumin levels and risk of developing thyroid cancer [Hazard Ratio for albumin ≤ 40 g/L: 1.50 (95% Confidence Interval = 1.04-2.16)]. When stratified by a metabolic score, we observed similar association for albumin with higher HR among those with metabolic score ≥ 1, as compared to those with metabolic score of 0 [HR 1.98 (95% CI = 1.11-3.54) vs 1.17 (95% CI = 0.72-1.89)] (

Indexed as

albuminAMORIS cohortcox analysisserum inflammatory markersthyroid cancer

Identifiers

PMID29416653
PMCPMC5787509
OpenAlexW2773829353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.